Intensity Therapeutics Inc (INTS)
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for cancer with both regional and systemic activity in the United States. The company’s lead candidate, INT230-6, is being evaluated in Phase 3 clinical studies for soft tissue sarcoma and in Phase 2 trials for neoadjuvant and metastatic triple-negative breast cancer. Incorporated in 2012 and based in Shelton, Connecticut, Intensity Therapeutics trades on the NASDAQ as common stock under the symbol INTS.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-INTS
|
$6.43
|
39.8% Upside
|
Undervalued
|
$24.80
|
439.1% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-1.2x
|
1.2x
|
—
|
12.703 M
|
2.29 M
|
0.8%
|
91.6%
|
-8.0
|
—
|
84.8%
|
